Similar articles

• New combinations in metastatic colorectal cancer: what are our expectations?

  Hurwitz H. Hurwitz H. Oncologist. 2005 May;10(5):320-2. doi: 10.1634/theoncologist.10-5-320. Oncologist. 2005. PMID: 15851788 Review. No abstract available.
• [Application of monoclonal antibody in combination with irinotecan in the treatment of colorectal cancer].

  Li J. Li J. Zhonghua Zhong Liu Za Zhi. 2006 Oct;28(10):796-7. Zhonghua Zhong Liu Za Zhi. 2006. PMID: 17366800 Review. Chinese. No abstract available.
• [Improving longevity in advanced intestinal cancer].

  Schmoll HJ. Schmoll HJ. Krankenpfl J. 2005;43(1-3):48. Krankenpfl J. 2005. PMID: 15912837 German. No abstract available.
• Cetuximab in colon cancer.

  Costa AF, Sander GB, Picon PD. Costa AF, et al. N Engl J Med. 2004 Oct 7;351(15):1575-6; author reply 1575-6. N Engl J Med. 2004. PMID: 15473024 No abstract available.
• Treatment with cetuximab, bevacizumab and irinotecan in heavily pretreated patients with metastasized colorectal cancer.

  Halama N, Herrmann C, Jaeger D, Herrmann T. Halama N, et al. Anticancer Res. 2008 Nov-Dec;28(6B):4111-5. Anticancer Res. 2008. PMID: 19192669